ES2157224T3 - Derivados de 5-arilindol y su uso como agonistas de serotonina (5-ht 1). - Google Patents

Derivados de 5-arilindol y su uso como agonistas de serotonina (5-ht 1).

Info

Publication number
ES2157224T3
ES2157224T3 ES93923389T ES93923389T ES2157224T3 ES 2157224 T3 ES2157224 T3 ES 2157224T3 ES 93923389 T ES93923389 T ES 93923389T ES 93923389 T ES93923389 T ES 93923389T ES 2157224 T3 ES2157224 T3 ES 2157224T3
Authority
ES
Spain
Prior art keywords
compounds
members
agonists
ring
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93923389T
Other languages
English (en)
Spanish (es)
Inventor
John Eugene Macor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2157224T3 publication Critical patent/ES2157224T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
ES93923389T 1992-11-02 1993-10-19 Derivados de 5-arilindol y su uso como agonistas de serotonina (5-ht 1). Expired - Lifetime ES2157224T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97075892A 1992-11-02 1992-11-02

Publications (1)

Publication Number Publication Date
ES2157224T3 true ES2157224T3 (es) 2001-08-16

Family

ID=25517470

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93923389T Expired - Lifetime ES2157224T3 (es) 1992-11-02 1993-10-19 Derivados de 5-arilindol y su uso como agonistas de serotonina (5-ht 1).

Country Status (27)

Country Link
US (1) US5886008A (enExample)
EP (2) EP0666858B1 (enExample)
JP (1) JP2788551B2 (enExample)
KR (1) KR0163371B1 (enExample)
CN (1) CN1051313C (enExample)
AT (1) ATE202102T1 (enExample)
AU (1) AU685066B2 (enExample)
BR (1) BR9307348A (enExample)
CA (2) CA2340999C (enExample)
CZ (1) CZ283001B6 (enExample)
DE (1) DE69330351T2 (enExample)
DK (1) DK0666858T3 (enExample)
EG (1) EG20396A (enExample)
ES (1) ES2157224T3 (enExample)
FI (2) FI111257B (enExample)
GR (1) GR3036579T3 (enExample)
HU (1) HU222235B1 (enExample)
IL (1) IL107386A (enExample)
MY (1) MY109696A (enExample)
NO (1) NO309652B1 (enExample)
NZ (1) NZ257059A (enExample)
PL (1) PL176091B1 (enExample)
PT (1) PT666858E (enExample)
RU (1) RU2134266C1 (enExample)
TW (1) TW251284B (enExample)
WO (1) WO1994010171A1 (enExample)
ZA (1) ZA938137B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
AU686654B2 (en) * 1993-08-31 1998-02-12 Pfizer Inc. 5-arylindole derivatives
CN1067386C (zh) * 1994-02-10 2001-06-20 辉瑞大药厂 作为苯并二氮杂䓬受体位的兴奋剂和拮抗药的5－杂芳基吲哚衍生物
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
CZ288897A3 (cs) * 1995-03-20 1998-02-18 Eli Lilly And Company V poloze 5-substituovaný 3-(1,2,3,6-tetrahydropyridin-4-yl)indol a 3-(piperidin-4-yl)indol a farmaceutický prostředek, který je obsahuje
AU7261196A (en) * 1995-10-10 1997-04-30 Eli Lilly And Company N-{2-substituted-3-(2-aminoethyl)-1h-indol-5-yl}-amides: new 5-ht1f agonists
TW589309B (en) 1997-07-03 2004-06-01 Bristol Myers Squibb Pharma Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
CA2334897A1 (en) * 1998-06-30 2000-01-06 Eli Lilly And Company Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
ATE503483T1 (de) 2002-10-30 2011-04-15 Merck Sharp & Dohme Hemmer der akt aktivität
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
AU2004233827B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
US7442709B2 (en) * 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
JP2007502822A (ja) * 2003-08-21 2007-02-15 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｃ−Ｋｉｔ阻害剤としてのＮ３−置換イミダゾピリジン誘導体
CA2540541C (en) 2003-10-03 2012-03-27 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
AU2004293078B2 (en) 2003-11-25 2012-01-19 3M Innovative Properties Company Substituted imidazo ring systems and methods
DE102004014304A1 (de) * 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen
WO2006084251A2 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
BRPI0709077A2 (pt) * 2006-03-22 2012-04-10 Janssen Pharmaceutica Nv derivados de alquilaminas cìclicas como inibidores da interação entre mdm2 e p53
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
ES2881081T3 (es) 2013-03-15 2021-11-26 Agenebio Inc Procedimientos y composiciones para mejorar la función cognitiva
MX369806B (es) 2015-04-29 2019-11-21 Janssen Pharmaceutica Nv Compuestos de indolona y su uso como moduladores del receptor ampa.
HUE053943T2 (hu) * 2015-04-29 2021-08-30 Janssen Pharmaceutica Nv Azabenzimidazolok és ampa receptor modulátorokként való alkalmazásuk
MX378389B (es) 2015-04-29 2025-03-10 Janssen Pharmaceutica Nv Compuestos de bencimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
AU2016255431B2 (en) 2015-04-29 2020-05-07 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators
AU2016268096B2 (en) 2015-05-22 2021-04-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
EP3371174B1 (en) 2015-11-06 2021-03-17 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives
WO2017076931A1 (en) 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives for use in the treatment of cns and related disorders
SG11201803796SA (en) 2015-11-06 2018-06-28 Hoffmann La Roche Indolin-2-one derivatives
CN108137555B (zh) 2015-11-06 2021-02-19 豪夫迈·罗氏有限公司 可用于治疗cns疾病的二氢吲哚-2-酮衍生物
CN111822047B (zh) * 2020-07-17 2022-05-27 曲阜师范大学 一种磁性介孔聚合离子液体负载催化合成吲哚类衍生物的方法
WO2025104491A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
WO2025104490A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
BE889931A (fr) * 1980-08-12 1982-02-11 Glaxo Group Ltd Derives indoliques, leur preparation et leurs applications en tant que medicaments
US4983622A (en) * 1984-02-06 1991-01-08 Eli Lilly And Company 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5340838A (en) * 1990-05-04 1994-08-23 Eli Lilly And Company Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
CA2042295A1 (fr) * 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
EG19650A (en) * 1990-06-07 1995-09-30 Wellcome Found Derivatives of indol and their use for treatment of megraine
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
EP0592438B1 (en) * 1990-10-15 1997-08-27 Pfizer Inc. Indole derivatives
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
FR2672602B1 (fr) * 1991-02-12 1993-06-04 Centre Nat Rech Scient Composes derives des beta-carbolines ligands du recepteur des benzodiazepines ayant un effet agoniste inverse et antagoniste vis-a-vis des benzodiazepines et medicaments les contenant.
US5229401A (en) * 1991-09-23 1993-07-20 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino benzo[b]thiophene compounds
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
US5378846A (en) * 1993-06-11 1995-01-03 Russian-American Institute For New Drug Development 1,2,3,4-tetrahydropyrrolo-[1,2-a]-pyrazine derivatives

Also Published As

Publication number Publication date
CA2148380A1 (en) 1994-05-11
NO309652B1 (no) 2001-03-05
FI20002505L (fi) 2000-11-15
PL176091B1 (pl) 1999-04-30
HU222235B1 (hu) 2003-05-28
DK0666858T3 (da) 2001-08-27
AU5329494A (en) 1994-05-24
EP1094064A1 (en) 2001-04-25
CZ283001B6 (cs) 1997-12-17
CA2340999A1 (en) 1994-05-11
US5886008A (en) 1999-03-23
CN1094727A (zh) 1994-11-09
DE69330351D1 (de) 2001-07-19
CZ110895A3 (en) 1995-11-15
BR9307348A (pt) 1999-05-11
PL308669A1 (en) 1995-08-21
MY109696A (en) 1997-04-30
NO951633D0 (no) 1995-04-28
KR0163371B1 (ko) 1998-12-01
WO1994010171A1 (en) 1994-05-11
KR950704313A (ko) 1995-11-17
CA2148380C (en) 2001-08-14
GR3036579T3 (en) 2001-12-31
RU95109927A (ru) 1997-01-10
FI934825A0 (fi) 1993-11-01
ZA938137B (en) 1995-05-02
TW251284B (enExample) 1995-07-11
EP0666858B1 (en) 2001-06-13
RU2134266C1 (ru) 1999-08-10
CA2340999C (en) 2005-01-04
FI934825L (fi) 1994-05-03
IL107386A0 (en) 1994-01-25
NZ257059A (en) 1997-07-27
EP0666858A1 (en) 1995-08-16
ATE202102T1 (de) 2001-06-15
FI111257B (fi) 2003-06-30
EG20396A (en) 1999-02-28
CN1051313C (zh) 2000-04-12
NO951633L (no) 1995-04-28
FI20002505A7 (fi) 2000-11-15
HUT66011A (en) 1994-08-29
PT666858E (pt) 2001-09-28
DE69330351T2 (de) 2001-09-20
JP2788551B2 (ja) 1998-08-20
AU685066B2 (en) 1998-01-15
JPH07508759A (ja) 1995-09-28
IL107386A (en) 1999-03-12

Similar Documents

Publication Publication Date Title
ES2157224T3 (es) Derivados de 5-arilindol y su uso como agonistas de serotonina (5-ht 1).
BG101806A (bg) Индолови производни като антагонисти на 5-нт рецептори
AR004320A1 (es) Nuevos compuestos de pirimidina condensados biciclicos; un procedimiento para su preparacion; composiciones farmaceuticas que los contienen y su usocomo agentes terapeuticos, en particular como inhibidores de la tirosina quinasa.
MX9307062A (es) Derivado de quinuclidina para el tratamiento de los trastornos inflamatorios y del sistema nervioso central.
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
ES2132223T3 (es) Derivados de indol condensados en calidad de antagonistas del receptor 5-ht4.
ES2065691T3 (es) Derivados de quinuclidina.
ES2084361T3 (es) Derivados de quinuclidina.
ES8602763A1 (es) Un procedimiento para la preparacion de n-(heterociclilbiciclo)-4-piperidinaminas.
ES2160596T3 (es) Derivados de quinuclidina como antagonistas de la sustancia p.
ES2083569T3 (es) Nuevos derivados de ariletenileno y procedimiento para su preparacion.
AR029215A1 (es) Derivados de benzazol y tautomeros de los mismos utiles en el tratamiento de desordenes en los sistemas de autoinmunidad y neuronales, uso de dichos derivados en la preparacion de composiciones farmaceuticas aplicables en el tratamiento de dichos desordenes, metodo prar inhibir la expresion y/o acti
AR005166A1 (es) Compuestos de quinolina y quinazolina, su uso, un procedimiento para producirlos, formulaciones farmaceuticas que los incluyen y compuesto utilescomo intermedios en dicho procedimiento.
UA27749C2 (uk) Заміщені циклопропіламіно-1,3,5-триазини, їх оптичні ізомери, рацемічні суміші чи їх солі приєднання нетоксичних фармацевтично прийнятних кислот, що мають фармакологічну активність, спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
FI980471A0 (fi) 1,3-substituoidut sykloalkeenit ja sykloalkaanit keskushermostoon vaikuttavina aineina
SE9702564D0 (sv) New compounds
EA199900161A1 (ru) Производные пиридазино [4,5-в]-хинолин-5-оксида, их получение и применение в качестве антагонистов глицина
AR012870A1 (es) Derivados de ergolina ([6ar, 9r, 10ar]-6-[4-(5-bromo-7-metil-4,6,6a,7,8,9, 10,10a-octahidro-indol[4,3-fg]quinolin-9-carbonil)-piperazin-1-il]-1-metil-1h-piridin-2-ona), proceso para su produccion, composicion farmaceutica, y su uso para la fabricacion de un medicamento para el tratamiento de depresi
ES2171911T3 (es) Poliaminas conformacionalmente restringidas y su uso como agentes antineoplasicos.
ES2089255T3 (es) N-(ariloxialquil)heteroaril-8-azabiciclo(3.2.1)octanos, compuestos intermedios y un procedimiento para su preparacion y su uso como medicamentos.
DE69217511D1 (de) Pyridazindionderivate, ihre Herstellung und Verwendung als Arzneimittel
ES2097652T3 (es) Compuestos de (1,2,4)triazolo(4,3-a)quinoxalina, su preparacion y uso.
PE25998A1 (es) DERIVADOS DE OCTAHIDRO-PIRROLO(1,2-a)-PIRAZINA 2,7-SUSTITUIDOS
ES2104370T3 (es) Derivados de (arilalquilaminobencil)aminopropionamidas sustituidas, su preparacion y utilizacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 666858

Country of ref document: ES